Business Context and Reporting Period
This Form 8-K filing by Charles River Laboratories International, Inc. (CRL) was submitted on January 8, 2026. The report details a significant leadership transition plan announced by the Board of Directors, effective May 5, 2026.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and governance changes.
Material Changes
- Executive Leadership: James C. Foster will step down as CEO and Chairman. Birgit Girshick, currently COO, will be appointed CEO.
- Board Composition: Dr. Martin Mackay will become Chair of the Board. The Board size will increase from 11 to 12 members to accommodate Ms. Girshick's appointment as a director.
- Compensation Adjustments:
- Ms. Girshick's base salary increases to $1,200,000 effective February 1, 2026.
- Ms. Girshick's target annual cash incentive will be 100% of base salary effective May 1, 2026.
- Ms. Girshick received an initial equity grant with a target fair market value of $9,000,000 (80% performance share units, 20% restricted stock units).
- Mr. Foster received a restricted stock unit grant with a fair market value of $3,000,000, vesting in a 2-year cliff.
Guidance, Outlook, and Risks
The filing contains no financial guidance or operational outlook. Key contingencies and risks include:
- Change in Control Provisions: Ms. Girshick's agreement includes a Change in Control provision entitling her to a severance package equal to three times her annual base salary plus target bonus, plus three years of medical benefits, if terminated without cause or for good reason within one year of a change in control.
- Shareholder Consent: The Board expansion required limited consent from Elliott Investment Management L.P. and affiliates under a Cooperation Agreement dated May 6, 2025.
Investor Verification Checklist
- Verify the exact vesting schedule and performance metrics for Ms. Girshick's $9,000,000 equity grant in the upcoming 10-K filing.
- Confirm the terms of the amended Change in Control Agreement for Ms. Girshick prior to the May 5, 2026 transition date.
- Monitor the 2026 Annual Meeting of Shareholders for the formal election of Ms. Girshick to the Board.
- Review the full text of Ms. Girshick's letter agreement filed as an exhibit to the 2025 Form 10-K for complete compensation details.